India · Delayed Price · Currency is INR Biocon Statistics
Total Valuation
Biocon has a market cap or net worth of INR 596.45 billion. The enterprise value is 763.29 billion.
| Market Cap | 596.45B |
| Enterprise Value | 763.29B |
Important Dates
The next estimated earnings date is Thursday, February 12, 2026.
| Earnings Date | Feb 12, 2026 |
| Ex-Dividend Date | Jul 4, 2025 |
Share Statistics
Biocon has 1.62 billion shares outstanding. The number of shares has increased by 3.91% in one year.
| Current Share Class | 1.62B |
| Shares Outstanding | 1.62B |
| Shares Change (YoY) | +3.91% |
| Shares Change (QoQ) | +7.11% |
| Owned by Insiders (%) | 46.00% |
| Owned by Institutions (%) | 22.98% |
| Float | 708.71M |
Valuation Ratios
The trailing PE ratio is 94.40 and the forward PE ratio is 49.64. Biocon's PEG ratio is 1.29.
| PE Ratio | 94.40 |
| Forward PE | 49.64 |
| PS Ratio | 3.62 |
| PB Ratio | 1.80 |
| P/TBV Ratio | n/a |
| P/FCF Ratio | 30.50 |
| P/OCF Ratio | 14.34 |
| PEG Ratio | 1.29 |
Enterprise Valuation
The stock's EV/EBITDA ratio is 22.06, with an EV/FCF ratio of 39.04.
| EV / Earnings | 157.22 |
| EV / Sales | 4.63 |
| EV / EBITDA | 22.06 |
| EV / EBIT | 44.43 |
| EV / FCF | 39.04 |
Financial Position
The company has a current ratio of 1.16, with a Debt / Equity ratio of 0.50.
| Current Ratio | 1.16 |
| Quick Ratio | 0.72 |
| Debt / Equity | 0.50 |
| Debt / EBITDA | 4.78 |
| Debt / FCF | 8.46 |
| Interest Coverage | 1.76 |
Financial Efficiency
Return on equity (ROE) is 2.55% and return on invested capital (ROIC) is 3.38%.
| Return on Equity (ROE) | 2.55% |
| Return on Assets (ROA) | 1.79% |
| Return on Invested Capital (ROIC) | 3.38% |
| Return on Capital Employed (ROCE) | 3.69% |
| Weighted Average Cost of Capital (WACC) | 5.24% |
| Revenue Per Employee | 10.03M |
| Profits Per Employee | 295,676 |
| Employee Count | 16,420 |
| Asset Turnover | 0.27 |
| Inventory Turnover | 1.24 |
Taxes
In the past 12 months, Biocon has paid 1.48 billion in taxes.
| Income Tax | 1.48B |
| Effective Tax Rate | 16.29% |
Stock Price Statistics
The stock price has increased by +1.13% in the last 52 weeks. The beta is 0.18, so Biocon's price volatility has been lower than the market average.
| Beta (5Y) | 0.18 |
| 52-Week Price Change | +1.13% |
| 50-Day Moving Average | 384.25 |
| 200-Day Moving Average | 365.94 |
| Relative Strength Index (RSI) | 43.14 |
| Average Volume (20 Days) | 3,439,847 |
Short Selling Information
| Short Interest | n/a |
| Short Previous Month | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | n/a |
Income Statement
In the last 12 months, Biocon had revenue of INR 164.76 billion and earned 4.86 billion in profits. Earnings per share was 3.90.
| Revenue | 164.76B |
| Gross Profit | 98.18B |
| Operating Income | 17.18B |
| Pretax Income | 9.11B |
| Net Income | 4.86B |
| EBITDA | 34.01B |
| EBIT | 17.18B |
| Earnings Per Share (EPS) | 3.90 |
Balance Sheet
The company has 61.04 billion in cash and 165.36 billion in debt, with a net cash position of -104.32 billion or -64.46 per share.
| Cash & Cash Equivalents | 61.04B |
| Total Debt | 165.36B |
| Net Cash | -104.32B |
| Net Cash Per Share | -64.46 |
| Equity (Book Value) | 330.55B |
| Book Value Per Share | 207.92 |
| Working Capital | 25.27B |
Cash Flow
In the last 12 months, operating cash flow was 41.59 billion and capital expenditures -22.04 billion, giving a free cash flow of 19.55 billion.
| Operating Cash Flow | 41.59B |
| Capital Expenditures | -22.04B |
| Free Cash Flow | 19.55B |
| FCF Per Share | 12.08 |
Margins
Gross margin is 59.59%, with operating and profit margins of 10.43% and 2.95%.
| Gross Margin | 59.59% |
| Operating Margin | 10.43% |
| Pretax Margin | 5.53% |
| Profit Margin | 2.95% |
| EBITDA Margin | 20.64% |
| EBIT Margin | 10.43% |
| FCF Margin | 11.87% |
Dividends & Yields
This stock pays an annual dividend of 0.50, which amounts to a dividend yield of 0.13%.
| Dividend Per Share | 0.50 |
| Dividend Yield | 0.13% |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | 13.78% |
| Buyback Yield | -3.91% |
| Shareholder Yield | -3.78% |
| Earnings Yield | 0.81% |
| FCF Yield | 3.28% |
Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | |
| Lynch Upside | |
| Graham Number | |
| Graham Upside |
Stock Splits
The last stock split was on June 12, 2019. It was a forward split with a ratio of 2.
| Last Split Date | Jun 12, 2019 |
| Split Type | Forward |
| Split Ratio | 2 |
Scores
Biocon has an Altman Z-Score of 1.71 and a Piotroski F-Score of 7. A Z-score under 3 suggests an increased risk of bankruptcy.
| Altman Z-Score | 1.71 |
| Piotroski F-Score | 7 |